Marksans Pharma Limited has made a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Nomination and Remuneration Committee (designated as the Compensation Committee) of the company approved the grant of 300,000 (Three Lakh) stock options to certain eligible employees of the company and its subsidiaries. The grant was approved on May 25, 2026, during a meeting that commenced at 04:50 p.m. and concluded at 05:25 p.m.
This approval follows special resolutions passed by shareholders at the Annual General Meetings held on September 24, 2024, and August 8, 2025. The grant also follows in-principle approvals received from both BSE Limited (on September 17, 2025) and the National Stock Exchange of India Limited (on September 18, 2025).
The disclosure is made in compliance with SEBI Circular bearing Ref. No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.
Key Terms of the ESOP Grant (From Annexure-A):
- Name of the Scheme: Marksans Employees Stock Option Scheme 2024
- Number of Options Granted: 300,000 stock options
- Date of Grant: May 25, 2026
- Compliance: The scheme complies with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
- Total Shares Covered: 300,000 equity shares of face value ₹1 each
- Exercise Price: ₹10 per stock option
- Vesting Period: One (1) year from the date of grant
- Exercise Period: Two (2) years from the date of vesting
- Current Status: Options have been granted but not yet vested, exercised, lapsed, or varied
Financial Impact:
The disclosure does not quantify the immediate financial impact of the grant. The potential dilution from the exercise of all 300,000 options is not calculated in terms of diluted earnings per share at this stage.